InflaRx on large white.jpg
InflaRx Reports First Quarter 2021 Financial & Operating Results
May 12, 2021 07:30 ET | InflaRx N.V.
Severe COVID-19 trial enrollment reaches 178 patients; interim analysis expected in Q3 At the FDA’s suggestion, planning to request a Type A meeting to further discuss primary endpoint for the Phase...
InflaRx on large white.jpg
InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study
May 11, 2021 16:30 ET | InflaRx N.V.
U.S. IXPLORE Phase II trial achieved its objective; vilobelimab was shown to be safe and well tolerated in patients with ANCA-associated vasculitis when added to current standard of careEU IXCHANGE...
InflaRx on large white.jpg
InflaRx Completes Enrollment of Vilobelimab Phase IIa Study in Pyoderma Gangraenosum
April 15, 2021 07:30 ET | InflaRx N.V.
Target enrollment of 18 patients reached across three different dose groupsInterim results will be available by the end of 2021 with final results expected in 2022Initial positive data from the first...
InflaRx on large white.jpg
InflaRx Reports Full Year 2020 Financial & Operating Results
March 25, 2021 06:30 ET | InflaRx N.V.
Submitted a Special Protocol Assessment to the FDA for Phase III program evaluating vilobelimab in Hidradenitis Suppurativa (HS) in Q1 2021Phase III trial in Severe COVID-19 is ongoing and recruiting...
InflaRx on large white.jpg
InflaRx to Present at Upcoming Investor Conferences
March 03, 2021 07:30 ET | InflaRx N.V.
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will present at...
InflaRx_1920x1080_50px spacing.jpg
InflaRx Announces Closing of $75 Million Public Offering of Common Shares and One-Year Warrants
March 01, 2021 16:01 ET | InflaRx N.V.
JENA, Germany, March 01, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement...
Inflarx-Logo_klein.jpg
InflaRx Announces Pricing of $75 Million Public Offering of Common Shares and One-Year Warrants
February 25, 2021 08:30 ET | InflaRx N.V.
JENA, Germany, Feb. 25, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
Inflarx-Logo_klein.jpg
InflaRx Announces Proposed Offering of Common Shares and One-Year Warrants
February 24, 2021 16:01 ET | InflaRx N.V.
JENA, Germany, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
Inflarx-Logo_klein.jpg
InflaRx Announces Presentation of New C5a and Vilobelimab (IFX-1) Data from Phase IIB SHINE Study at the 2021 Virtual European Hidradenitis Suppurativa Foundation Conference
February 11, 2021 07:30 ET | InflaRx N.V.
Significantly elevated baseline C5a levels occur in hidradenitis suppurativa (HS) patientsVilobelimab dose-dependently suppresses C5a levels over time accompanied by the previously reported reduction...
Inflarx-Logo_klein.jpg
InflaRx Provides Update on Vilobelimab (IFX-1) Development
January 11, 2021 07:30 ET | InflaRx N.V.
Multiple data readouts expected in 2021Phase II trial in patients with cutaneous squamous cell carcinoma expected to start in the first half of 2021 JENA, Germany, Jan. 11, 2021 (GLOBE...